Sector movers: Hikma weighs on pharma sector
17th Mar 2010 11:40
Hikma Pharmaceuticals is weighing on the pharmaceutical sector even after it reported a 33% increase in 2009 operating profit and said it was confident of continuing growth. Broker Panmure Gordon was predicting yesterday that results from Hikma would be ahead of market expectations, so the in-line
Read moreFTSE 250 movers: Arriva pulls away
17th Mar 2010 11:39
Arriva has raced into the lead to lead the FTSE 250 after the rail and bus group said it had received an approach about a possible offer. Shares in the company climbed yesterday amid rumours of a possible 700p-a-share bid from German transport operator Deutsche Bahn. Singaporean firm ComfortDelGr
Read moreHikma sees low teens sales growth in 2010
17th Mar 2010 07:30
Hikma Pharmaceuticals reported a 33% increase in 2009 operating profit and said it was confident of continuing growth. The Jordan based drug maker said it expects to increase sales in the "low-teens" in 2010. Operating profit rose 33% for the year ended 31 December 2009 to £107.3m. Revenue for the
Read moreWednesday preview: UK unemployment, MPC minutes, Hikma
16th Mar 2010 18:03
In the absence of any announcements expected from FTSE 100 companies attention may be focused on economic data on Wednesday. Claimant count unemployment for February is expected to show a small rise, following on from the 23,500 increase in January. Forecasting agency IHS Global Insight is tipping
Read moreHikma to market BioCryst drug in MENA region
11th Jan 2010 14:32
Hikma Pharmaceuticals has signed an exclusive agreement to market BioCryst's H1N1 treatment peramivir with governments in the Middle East and North Africa (MENA) region. 'This agreement reinforces our position as the partner of choice in the MENA region,' said chief executive Said Darwazah. 'BioC
Read morePetropavlovsk chief banks £24m
18th Dec 2009 16:17
Pavel Maslovskiy, chief executive of Petropavlovsk, is taking advantage of the near-record gold price to bank some cash with the sale of £24m worth of shares in the Russian gold miner. Companies associated with Dr Maslovskiy sold 2m shares at £11.93 per share. The off-market sale was to a non-relat
Read moreThursday preview: Diageo, Hikma, IMI
26th Aug 2009 14:48
Alcoholic drinks group Diageo's trading update is expected to report an improvement in full-year pre-tax profits on Thursday, with the market consensus hovering around £2.bn, compared to £2.09bn last year. This is despite an anticipated decline in revenue to around £9.25bn from £10.64bn in the year
Read moreLondon close: Footsie adds to week's gains
17th Jul 2009 16:28
Footsie rounded off its best week since March with more gains. Miners were prominent among the risers. Eurasian Natural Resources, Xstrata, Vedanta Resources and Rio Tinto are doing well. British Airways climbed after saying it is raising £600m, including a £300m convertible issue and another £30
Read moreLondon midday: Footsie on course for strong week
17th Jul 2009 12:15
London is heading for its best week in three months as miners climb, while British Airways is flying high despite a £100m first quarter loss. The FTSE 100 got off to a decent start following a late rally on Wall Street last night and better than expected numbers from IBM and Google and has carried
Read moreLondon open: Decent start for Footsie
17th Jul 2009 08:44
London's blue chips have opened brightly after the late rally on Wall St and better than expected numbers from IBM and Google. British Airways is an early riser despite a £300m convertible issue, shuffling of its pension guarantees to free up another £300m and a first quarter loss of £100m. That lo
Read moreLondon pre-open: Shares set to rise
17th Jul 2009 07:32
London's blue chips are expected to gain in early dealings on Friday with sentiment likely to get a boost from better than expected numbers from IBM and internet giant Google in the US overnight. Traders expect Footsie to open 30 points higher. British Airways has launched a £300m convertible debt
Read moreHikma signs licensing deal with Faes Farma
17th Jul 2009 07:17
Hikma Pharmaceuticals has signed a licensing agreement for the anti-histamine Bilastine with Spain's Faes Farma for the Middle East & North Africa (MENA) region. Through this agreement Faes Farma grants exclusive rights for the manufacture and distribution of Bilastine to Hikma for 17 MENA countri
Read moreHikma confirms full year guidance
14th May 2009 07:58
Pharmaceutical firm Hikma said it maintains its guidance on delivering full-year revenue growth of 10-15% and gross margin improvement of 1-2%. The group said it is on track to deliver Branded sales growth in line with expectations for the full year, while the Generics business is performing ahead
Read more